Oslo, 7 June 2021: Reference is made to the stock exchange release by EXACT Therapeutics AS ("EXACT-Tx" or the "Company") on 7 June 2021 regarding a share capital increase in connection with the Company's restricted stock unit (RSU) programme.
 
Masha Strømme, chair of EXACT-Tx, has through her majority owned company PAACS Invest AS, subscribed for 6,489 shares at NOK 20.804 per share. Following this transaction, Masha Strømme will hold 2,684,739 shares in EXACT-Tx through PAACS Invest AS.
 
Sir William Castell, vice-chair of EXACT-Tx, has subscribed for 9,998 shares at NOK 20.804 per share. Following this transaction, Sir William Castell will hold 342,498 shares in EXACT-Tx.
 
Hans Henrik Klouman, board member of EXACT-Tx, has subscribed for 2,900 shares at NOK 20.804 per share. Following this transaction, Hans Henrik Klouman will hold 402,650 shares in EXACT-Tx through Virkelyst AS.
 
Aitana Peire, board member of EXACT-Tx, has subscribed for 5,030 shares at NOK 20.804 per share. Following this transaction, Aitana Peire will hold 5030 shares in EXACT-Tx.

About EXACT-Tx
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com